Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Administration of cross-sex hormones to male-to-female transsexual subjects, usually oestrogens + often anti-androgens, such as cyproterone acetate, carries a risk of venous thromboembolism (VTE). VTE usually occurs in the first year of oestrogen administration. Ethinyl oestradiol, due to its chemical structure, was in 2003 identified as a major factor in the occurrence of VTE. Most clinics do not prescribe ethinyl oestradiol any longer, but people who take hormones without medical supervision use often oral contraceptives containing ethinyl oestradiol, many times in overdose. Cessation of use of ethinyl oestradiol and peri-operative thrombosis prophylaxis for surgery have reduced prevalence rate of VTE. Other oral oestrogens should not be overdosed, and transdermal oestrogen is to be preferred. Thrombosis prophylaxis for surgery is mandatory. It seems advisable to stop hormone use at least 2 weeks before major surgery, to be resumed only after 3 weeks following full mobilisation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
Thrombotic stroke and myocardial infarction with hormonal contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111840 · Cited by 607
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569 · cited 3×
“In a metaanalysis of randomised controlled trials of oral HRT users, the risk of VTE was clearly increased with an odds ratio of 2.05 (95% CI: 1.44–2.92) (Canonico et al., 2008).”
BackgroundInfluentialLong-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience
Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1809 · Cited by 308 · cited 1×
“Administered by a knowledgeable physician, hormone treatment is acceptably safe (Gooren et al., 2008; Hembree et al., 2009; Asscheman et al., 2011).”
BackgroundSelf-citationSitruk-Ware, R., & Nath, A. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.09.004 · Cited by 247 · cited 1×
“The prothrombotic effect of ethinyl oestradiol was ascribed to its molecular structure rather than to the first-pass liver effect which ethinyl oestradiol shares with all other types of oral oestrogens (Toorians et al., 2003; Sitruk-Ware & Nath, 2013).”
BackgroundEffects of high dose oestrogen therapy on circulating inflammatory markers
Wilson, R., Spiers, A., Ewan, J., Johnson, P., Jenkins, C., & Carr, S. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.01.009 · Cited by 59 · cited 2×
“Our search in PubMed found 10 papers between 1980 and 2012 reporting VTE in MtF subjects treated with CSHT and provided sufficient information on numbers of MtF subjects treated with CSHT, types of hormone treatment and documented duration of use, to quantify the risk of VTE (Asscheman et al., 1989; Prior et al., 1989…”
BackgroundMethod
Cited by
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., et al. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2100644 · Cited by 2,698
Self-citationHembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01658 · Cited by 2,328
“A more recent multinational study reported only 10 cases of VTE from a cohort of 1073 subjects (168).”
Self-citationEndocrinology of Transgender Medicine
T’Sjoen, G., Arcelus, J., Gooren, L., Klink, D. T., & Tangpricha, V. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00011 · Cited by 314
Self-citationIntegrated and Gender-Affirming Transgender Clinical Care and Research
Reisner, S. L., Radix, A., & Deutsch, M. B. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001088 · Cited by 311
Hormone therapy for transgender patients
Unger, C. A. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.04 · Cited by 245
“Use of oral ethinyl estradiol appears to be strongly associated with cardiovascular events (30) and should therefore be avoided as a mainstay therapy for patients (31).”
BackgroundWeinand, J. D., & Safer, J. D. (2015) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2015.02.003 · Cited by 175
“In one of the largest studies to-date, Asscheman et al. (2014), observed the lowest reported rate of 1% of adults experiencing VTE among 1076 MTF individuals for an average follow of 5.4 years [2].”
BackgroundInfluentialDefreyne, J., Vantomme, B., Van Caenegem, E., Wierckx, K., De Blok, C. J. M., Klaver, M., Nota, N. M., Van Dijk, D., Wiepjes, C. M., Den Heijer, M., et al. (2018) · Andrology · doi:10.1111/andr.12485 · Cited by 114
“Known side effects of the administration of estrogens and/or anti-androgens include the occurrence of thromboembolic complications (Asscheman et al., 2014), hyperprolactinemia (van Kesteren et al.”
BackgroundPrimary sigmoid vaginoplasty in transwomen: technique and outcomes.
Salgado, C. J., Nugent, A., Kuhn, J., Janette, M., & Bahna, H. (2018) · BioMed Research International · doi:10.1155/2018/4907208 · Cited by 64
“However, there are no tests to monitor synthetic estrogens and no evidence that establishes a risk optimization protocol in transwomen [29, 30, 34].”
BackgroundTack, L. J. W., Heyse, R., Craen, M., Dhondt, K., Bossche, H. V., Laridaen, J., & Cools, M. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.03.251 · Cited by 52
Metadata
- Authors
- Asscheman, H., T'Sjoen, G., Lemaire, A., Mas, M., Meriggiola, M. C., Mueller, A., Kuhn, A., Dhejne, C., Morel-Journel, N., & Gooren, L. J.
- Venue
- Andrologia
- Publisher
- Hindawi Limited
- Published
- 2013-08-15
- Volume
- 46
- Issue
- 7
- Pages
- 791-795
- ISSN
- 0303-4569 (ISSN-L)
- OpenAlex
- W2022939168
- Cited by
- 132
- References
- 6
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.